Peptide Research Library

Exenatide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes published evidence, dosing context, safety considerations, and Australian legal status for Exenatide.

What the sources say

• In EXSCEL, a randomized cardiovascular-outcomes trial of once-weekly extended-release exenatide in type 2 diabetes, the primary cardiovascular outcome met non-inferiority versus placebo but did not show statistically significant superiority (hazard ratio 0.91, 95% CI 0.83–1.00; P=0.06 for superiority). (Human clinical trials; Holman et al., "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes" (EXSCEL), 2017-09-14)
• The EDICT trial compared initial triple therapy (exenatide plus metformin and pioglitazone) with a sequential escalation strategy in newly diagnosed type 2 diabetes and reported better glycaemic control and weight outcomes for the initial combination. This supports that specific multi-drug regimen in its study population; it cannot isolate exenatide's contribution or establish universal synergy. (Human clinical trials; Abdul-Ghani et al., "Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy" (EDICT), 2015-01-07)
• WebMD patient reviews include self-reports of appetite changes, nausea and variable experiences while taking Byetta; the entries are old, unverified, and do not establish clinical effect, incidence or current product quality. (Community reports; WebMD, "Exenatide (Byetta) User Reviews", 2026-10-28)
• The TGA cancelled the Byetta 5 microgram ARTG entry in 2024, so historical dosing information is not current supply guidance. (Educator material (not peer reviewed); TGA, "BYETTA 5 exenatide 5 micrograms/20 microlitres ... cancelled under section 30(1)(c)", 2024-04-23)
• Exenatide is a GLP-1 receptor agonist; the archived Australian TGA label covered Byetta and Bydureon presentations. (Educator material (not peer reviewed); TGA, Attachment: Product Information for exenatide (Byetta and Bydureon; AusPAR final 5 February 2013), 2013-02-05)
• Patient reviews report both favorable and unfavorable experiences, but self-selection, old product use, unknown co-treatments and lack of verification make them unsuitable for estimating risk or guiding treatment. (Community reports; WebMD, "Exenatide (Byetta) User Reviews", 2026-10-28)
• The archived Byetta and Bydureon Product Information identifies gastrointestinal effects and formulation-specific cautions; the document is historical and does not replace current clinical assessment or a current product label. (Educator material (not peer reviewed); TGA, Attachment: Product Information for exenatide (Byetta and Bydureon; AusPAR final 5 February 2013), 2013-02-05)
• The TGA lists the Byetta 5 microgram ARTG entry as cancelled effective 23 April 2024; a cancelled entry is not current approval for supply under that registration. (Educator material (not peer reviewed); TGA, "BYETTA 5 exenatide 5 micrograms/20 microlitres ... cancelled under section 30(1)(c)", 2024-04-23)
• The TGA lists the Byetta 10 microgram ARTG entry as cancelled effective 23 April 2024. (Educator material (not peer reviewed); TGA, "BYETTA 10 exenatide 10 micrograms/40 microlitres ... cancelled under section 30(1)(c)", 2024-04-23)
• The TGA lists the Bydureon prefilled-pen ARTG entry as cancelled effective 2 November 2023. These records do not establish the status of every exenatide product worldwide or any future Australian registration. (Educator material (not peer reviewed); TGA, "BYDUREON exenatide powder for injection pre-filled pen cancelled under section 30(1)(c)", 2023-11-02)
• The TGA lists the Bydureon powder vial-with-diluent ARTG entry as cancelled effective 29 June 2022. (Educator material (not peer reviewed); TGA, "BYDUREON exenatide powder for injection vial with diluent syringe cancelled under section 30(1)(c)", 2022-06-29)

Sources

1. Holman et al., "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes" (EXSCEL) (2017-09-14)
2. Abdul-Ghani et al., "Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy" (EDICT) (2015-01-07)
3. WebMD, "Exenatide (Byetta) User Reviews" (2026-10-28)
4. TGA, "BYETTA 5 exenatide 5 micrograms/20 microlitres ... cancelled under section 30(1)(c)" (2024-04-23)
5. TGA, Attachment: Product Information for exenatide (Byetta and Bydureon; AusPAR final 5 February 2013) (2013-02-05)
6. TGA, "BYETTA 10 exenatide 10 micrograms/40 microlitres ... cancelled under section 30(1)(c)" (2024-04-23)
7. TGA, "BYDUREON exenatide powder for injection pre-filled pen cancelled under section 30(1)(c)" (2023-11-02)
8. TGA, "BYDUREON exenatide powder for injection vial with diluent syringe cancelled under section 30(1)(c)" (2022-06-29)

Dosing, stacking and protocol details are not published here.